Trinity Capital Inc. (TRIN)
After hours:
| Previous Close | 14.90 |
| Open | 14.94 |
| Bid | 14.67 x 100 |
| Ask | 14.75 x 100 |
| Day's Range | 14.60 - 14.94 |
| 52 Week Range | 12.22 - 15.44 |
| Volume | |
| Avg. Volume | 476,080 |
| Market Cap | 737.231M |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 9.38 |
| EPS (TTM) | 1.57 |
| Earnings Date | Aug 07, 2024 |
| Forward Dividend & Yield | 2.04 (13.69%) |
| Ex-Dividend Date | Mar 27, 2024 |
| 1y Target Est | 15.56 |
PR NewswireTrinity Capital Inc. Expands Operations into Europe
Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity" or the "Company"), a leading provider of diversified financial solutions to growth-oriented companies, today announced its strategic expansion into Europe with the appointment of London-based Craig Fox as Managing Director. This initiative aligns with the Company's long-term vision of supporting high-growth companies globally.
PR NewswireMetabolon Secures $60 Million Credit Facility to Drive Growth and Innovation
Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announced that it has closed on a new $60 million credit facility. This significant investment, of which an initial $42.5 million was funded at closing, will be utilized to fuel the company's growth initiatives and expand its research and development efforts to further enhance its metabolomics platform.
PR NewswireTrinity Capital Inc. Provides $60 Million in Growth Capital to Metabolon
Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity"), a leading provider of diversified financial solutions to growth-stage companies, today announced the commitment of $60 million in growth capital to Metabolon, a global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications.
